Tandem Mapping of Protein Secondary Binding Sites
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional drug discovery methods are limited in identifying diverse small molecule options and exploiting secondary ligand binding sites on biological molecules, leading to biased drug development strategies that focus on endogenous ligand binding sites, restricting the potential for intervention strategies.
Innovation Solution
The method involves site-specific modification of biological molecules using activated polymer complexes that facilitate covalent bonding with polyalkylene oxide polymers and ligand moieties, enabling the identification and mapping of novel binding sites and ligands that modulate the activity of biological targets without prior structural or functional knowledge.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional drug discovery methods focus on endogenous ligand binding sites, then drug development strategy is simplified and targeted, but drug lead diversity is restricted and secondary binding sites are not exploited
Solution Approach 1:
The patent segments the protein surface into multiple distinct binding sites by using site-specific reactive groups as markers. This segmentation allows systematic exploration of secondary binding sites independent of the primary endogenous ligand binding site, thereby expanding drug lead diversity without requiring complete structural characterization of the entire protein surface.
Solution Approach 2:
The patent introduces site-specific reactive groups as intermediary markers to identify and map binding sites. These reactive groups serve as intermediaries that facilitate the attachment of diverse ligands to specific protein locations, enabling systematic exploration of binding sites without requiring prior structural knowledge of the protein.
2Reliability
If site-specific modification uses covalent bonding with polyalkylene oxide polymers, then safety and efficacy are enhanced and immunogenic responses are reduced, but manufacturing complexity increases
Solution Approach 1:
The patent applies local quality by attaching polyalkylene oxide polymers to specific localized sites on the protein molecule rather than uniform modification throughout. This site-specific modification preserves the functional integrity of the protein while enhancing safety and efficacy at the modified location, and reduces immunogenic responses by controlling the distribution and density of polymer attachments.
Solution Approach 2:
The patent utilizes parameter changes by varying the polyalkylene oxide polymer characteristics (molecular weight, chain length, composition) to optimize the balance between safety/efficacy enhancement and manufacturing complexity. Different polymer parameters can be selected based on the specific therapeutic application and target protein properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the systematic identification and modulation of covalent bonding activities on biological targets, expanding drug lead diversity by targeting distinct sites, thereby enhancing the safety and efficacy of biological molecules and reducing immunogenic responses.
Implementation Method 1
stable covalent bonding of such a reactive target group with a functional group linked to a ligand moiety and a polyalkylene oxide polymer
Implementation Method 2
noncovalent binding of potential ligands which, combined, identify and map binding sites
Data Source
AI summary
The present invention provides methods of discovering and mapping secondary binding sites on biological molecules (e.g., proteins), the effects, if any, of site occupancy on the primary function of the molecule, and the screening of small molecules against the secondary binding sites. The invention further provides novel complexes for modification of secondary binding sites and the resulting modified biological molecules.